X. Mou

Serum HDAC4 level in rheumatoid arthritis: Longitudinal change during treatment and correlation with clinical outcomes

X. Mou, Yi Jin, Du Jin, 2022, Journal of clinical laboratory analysis.

Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

Joseph A. DiGiuseppe, L. Medeiros, W. Wang, 2017, Leukemia.

Granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies treatment for COVID-19 patients: a meta-analysis

D. Jin, Z. Xu, A. Xi, 2022, medRxiv.

PBMC CDC42 reveals the disease activity and treatment efficacy of TNF inhibitor in patients with ankylosing spondylitis

Hengli Ye, X. Mou, Du Jin, 2022, Journal of clinical laboratory analysis.

The efficacy and safety of TNF inhibitor (golimumab) as salvage treatment in patients with refractory noninfectious uveitis

Shan-Hong Lu, X. Mou, Yi Jin, 2022, Inflammopharmacology.

Mycobacterium smegmatis msmeg_3314 is involved in pyrazinamide and fluoroquinolones susceptibility via NAD+/NADH dysregulation.

Y. Zhang, Yu Huang, J. Xie, 2020, Future microbiology.

The neutrophil-lymphocyte ratio and immunosuppressive acidic protein may be useful parameters for predicting depression among middle-aged patients with diffuse large B cell lymphoma.

Yajun Zhang, X. Mou, Ke Yi, 2021, Annals of palliative medicine.

A meta-analysis of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatment for COVID-19 patients

Shanshan Lei, Jinlan Guan, Zhenghao Xu, 2021, Therapeutic advances in chronic disease.